Will fixing the vasoactivity caused by hemoglobin-based oxygen carriers be enough?
Cabrales
Pedro
P
Tsai
Amy G
AG
D000818:Animals; D001802:Blood Substitutes / Q000009:adverse effects*; D006454:Hemoglobins / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D014661:Vasoconstriction / Q000187:drug effects*
D001802:Blood Substitutes; D006454:Hemoglobins; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors; D009569:Nitric Oxide